Additional file 10: of Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma

  • Noah Berlow (Creator)
  • Rishi Rikhi (Contributor)
  • Mathew Geltzeiler (Creator)
  • Jinu Abraham (Contributor)
  • Matthew N. Svalina (Creator)
  • Lara E. Davis (Creator)
  • Erin Wise (Creator)
  • Maria Mancini (Creator)
  • Jonathan Noujaim (Creator)
  • Atiya Mansoor (Contributor)
  • Michael J. Quist (Creator)
  • Kevin L. Matlock (Creator)
  • Martin W. Goros (Creator)
  • Brian S. Hernandez (Creator)
  • Yee C. Doung (Creator)
  • Khin Thway (Contributor)
  • Tomohide Tsukahara (Contributor)
  • Jun Nishio (Creator)
  • Elaine T. Huang (Creator)
  • Susan Airhart (Creator)
  • Carol J. Bult (Creator)
  • Regina Gandour-Edwards (Creator)
  • Robert G. Maki (Creator)
  • Robin L. Jones (Creator)
  • Joel E Michalek (Creator)
  • Milan Milovancev (Creator)
  • Souparno Ghosh (Contributor)
  • Ranadip Pal (Contributor)
  • Charles Keller (Creator)



Figure S10. Schematic of PTIM-informed U23674 rewiring experiment. An initial culture of U23674 is screened using the Roche screen. The same culture is used to seed 6 new cultures, which are grown until the cell population is sufficient for drug screening. Five of the 6 cultures were treated using single agents and drug combinations in low dosages (75â nM OSI-906, 50â nM GDC-0941) and one culture was left untreated. After treatment and incubation for 72â h, the compounds were removed the cells were screened using the Roche Orphan Kinome screen. (TIF 8496 kb)
Datos disponibles2019

Citar esto